OTCPK:TLPPF (Australia)
Â
Ordinary Shares
$
10.45
+0.15 (+1.46%)
10:08 PM EST
Current and historical daily PE Ratio for Telix Pharmaceuticals Ltd (
) from 2018 to May 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Telix Pharmaceuticals stock (TLPPF) PE ratio as of May 27 2024 is 966.88.
More Details
Telix Pharmaceuticals Ltd (TLPPF) PE Ratio (TTM) Chart
Telix Pharmaceuticals Ltd (TLPPF) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1219
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Telix Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-27 | 950.0 | 2024-03-22 | 745.5 |
| 2024-05-24 | 950.0 | 2024-03-21 | 796.4 |
| 2024-05-23 | 936.4 | 2024-03-20 | 718.2 |
| 2024-05-22 | 982.7 | 2024-03-19 | 718.2 |
| 2024-05-21 | 938.2 | 2024-03-18 | 768.2 |
| 2024-05-20 | 980.9 | 2024-03-15 | 702.3 |
| 2024-05-17 | 925.5 | 2024-03-14 | 676.8 |
| 2024-05-16 | 949.1 | 2024-03-13 | 684.5 |
| 2024-05-15 | 928.2 | 2024-03-12 | 704.5 |
| 2024-05-14 | 927.3 | 2024-03-11 | 704.5 |
| 2024-05-13 | 927.3 | 2024-03-08 | 722.7 |
| 2024-05-10 | 927.3 | 2024-03-07 | 685.5 |
| 2024-05-09 | 925.5 | 2024-03-06 | 684.5 |
| 2024-05-08 | 918.2 | 2024-03-05 | 684.5 |
| 2024-05-07 | 909.1 | 2024-03-04 | 732.7 |
| 2024-05-06 | 905.5 | 2024-03-01 | 739.1 |
| 2024-05-03 | 904.5 | 2024-02-29 | 749.1 |
| 2024-05-02 | 904.5 | 2024-02-28 | 716.4 |
| 2024-05-01 | 863.6 | 2024-02-27 | 719.1 |
| 2024-04-30 | 890.9 | 2024-02-26 | 636.4 |
| 2024-04-29 | 909.1 | 2024-02-23 | 625.5 |
| 2024-04-26 | 875.5 | 2024-02-22 | 697.3 |
| 2024-04-25 | 877.3 | 2024-02-21 | 697.3 |
| 2024-04-24 | 891.8 | 2024-02-20 | 697.3 |
| 2024-04-23 | 830.9 | 2024-02-16 | 697.3 |
| 2024-04-22 | 830.9 | 2024-02-15 | 690.0 |
| 2024-04-19 | 802.3 | 2024-02-14 | 709.1 |
| 2024-04-18 | 820.0 | 2024-02-13 | 709.1 |
| 2024-04-17 | 740.0 | 2024-02-12 | 709.1 |
| 2024-04-16 | 782.7 | 2024-02-09 | 709.1 |
| 2024-04-15 | 789.1 | 2024-02-08 | 709.1 |
| 2024-04-12 | 750.0 | 2024-02-07 | 705.5 |
| 2024-04-11 | 746.4 | 2024-02-06 | 709.1 |
| 2024-04-10 | 746.4 | 2024-02-05 | 712.7 |
| 2024-04-09 | 745.5 | 2024-02-02 | 709.1 |
| 2024-04-08 | 758.2 | 2024-02-01 | 703.6 |
| 2024-04-05 | 760.9 | 2024-01-31 | 697.3 |
| 2024-04-04 | 760.9 | 2024-01-30 | 719.1 |
| 2024-04-03 | 760.9 | 2024-01-29 | 709.1 |
| 2024-04-02 | 759.1 | 2024-01-26 | 678.0 |
| 2024-04-01 | 799.6 | 2024-01-25 | 670.0 |
| 2024-03-28 | 768.2 | 2024-01-24 | 670.0 |
| 2024-03-27 | 768.2 | 2024-01-23 | 668.2 |
| 2024-03-26 | 790.0 | 2024-01-22 | 655.5 |
| 2024-03-25 | 790.9 | 2024-01-19 | 672.7 |
Telix Pharmaceuticals Ltd (TLPPF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Telix Pharmaceuticals Ltd
ISIN : AU000000TLX2
Share Class Description:
TLPPF: Ordinary SharesDescription
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney), and glioblastoma (brain) cancer. Geographically, It operates through two reportable segments Commercial operations which include Commercial sales of Illuccix and other products after obtaining regulatory approvals and Product development includes Developing radiopharmaceutical products for commercialisation. This segment includes revenue received from license agreements before commercialization and research and development services. It operates in Australia, the United States, Belgium, and Japan.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers